Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
Jul 26, 2019
Product Development
Institute for Protein Design's de novo revolution
...from Bioeconomy Capital, Casdin Capital LLC, OS Fund, Sustainable Conversion Ventures, Universal Materials Incubator and
WRF Capital
...
Read More
BioCentury
|
May 31, 2019
Targets & Mechanisms
Targeting cancer evolution offers a way to foil drug resistance
...AppTec Co. Ltd., as well as Alexandria Venture Investments, Arch Venture Partners, Watson Fund and
WRF Capital
...
Read More
BioCentury
|
Aug 31, 2018
Financial News
ApoGen expands series A to $11M
...Arch Venture Partners, Eli Lilly and Co. (NYSE:LLY), Johnson & Johnson Innovation-JJDC Inc., Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Sep 13, 2017
Emerging Company Profile
Not PGE2's first Rodeo
...Venture, Eli Lilly and Co. , Johnson & Johnson Innovation -- JJDC Inc., Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Jul 28, 2017
Financial News
Accelerator leads Rodeo's series A
...Johnson & Johnson Innovation - JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ), Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Jul 25, 2017
Financial News
Accelerator leads Rodeo's series A round
...Johnson & Johnson Innovation - JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ), Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Mar 30, 2017
Emerging Company Profile
Resisting resistance
...Venture Partners , Eli Lilly and Co. , Johnson & Johnson Innovation- JJDC, Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Dec 14, 2016
Financial News
ApoGen completes venture financing
...Arch Venture Partners , Eli Lilly and Co. , Johnson & Johnson Innovation-JJDC, Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Dec 13, 2016
Financial News
ApoGen debuts with $7M
...NYSE:LLY), the Johnson & Johnson Innovation-JJDC venture arm of Johnson & Johnson (NYSE:JNJ), Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Feb 15, 2016
Financial News
M3 Biotechnology completes venture financing
...Seattle, Wash. Business: Neurology Date completed: 2016-02-11 Type: Venture financing Raised: $10 million Investors:
WRF Capital
...
Read More
Items per page:
10
1 - 10 of 41
BioCentury
|
Jul 26, 2019
Product Development
Institute for Protein Design's de novo revolution
...from Bioeconomy Capital, Casdin Capital LLC, OS Fund, Sustainable Conversion Ventures, Universal Materials Incubator and
WRF Capital
...
Read More
BioCentury
|
May 31, 2019
Targets & Mechanisms
Targeting cancer evolution offers a way to foil drug resistance
...AppTec Co. Ltd., as well as Alexandria Venture Investments, Arch Venture Partners, Watson Fund and
WRF Capital
...
Read More
BioCentury
|
Aug 31, 2018
Financial News
ApoGen expands series A to $11M
...Arch Venture Partners, Eli Lilly and Co. (NYSE:LLY), Johnson & Johnson Innovation-JJDC Inc., Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Sep 13, 2017
Emerging Company Profile
Not PGE2's first Rodeo
...Venture, Eli Lilly and Co. , Johnson & Johnson Innovation -- JJDC Inc., Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Jul 28, 2017
Financial News
Accelerator leads Rodeo's series A
...Johnson & Johnson Innovation - JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ), Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Jul 25, 2017
Financial News
Accelerator leads Rodeo's series A round
...Johnson & Johnson Innovation - JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ), Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Mar 30, 2017
Emerging Company Profile
Resisting resistance
...Venture Partners , Eli Lilly and Co. , Johnson & Johnson Innovation- JJDC, Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Dec 14, 2016
Financial News
ApoGen completes venture financing
...Arch Venture Partners , Eli Lilly and Co. , Johnson & Johnson Innovation-JJDC, Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Dec 13, 2016
Financial News
ApoGen debuts with $7M
...NYSE:LLY), the Johnson & Johnson Innovation-JJDC venture arm of Johnson & Johnson (NYSE:JNJ), Watson Fund,
WRF Capital
...
Read More
BioCentury
|
Feb 15, 2016
Financial News
M3 Biotechnology completes venture financing
...Seattle, Wash. Business: Neurology Date completed: 2016-02-11 Type: Venture financing Raised: $10 million Investors:
WRF Capital
...
Read More
Items per page:
10
1 - 10 of 41
Previous page
Next page